Skip to main content
Premium Trial:

Request an Annual Quote

Xagenic Raises C$20M in Private Financing Round

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Xagenic today announced that it has closed a Series B round of financing that brought in $20 million (US$18.8 million) in funding.

The Toronto-based company said that the proceeds would be used to support continued development and studies of its molecular diagnostics platform, which is intended for use in decentralized settings such as doctors' offices and clinics. Its core technology is the Amplified Redox Assay, or AuRA, which uses nanostructured microelectrodes for rapid enzyme-free detection of nucleic acids from clinical specimens without the need for sample extraction.

The Series B round was led by new investor Domain Associates, which was joined by existing investors including CTI Life Sciences Fund and the Ontario Emerging Technologies Fund. In conjunction with the financing, Jesse Treu, a partner at Domain Associates, will join Xagenic's Board of Directors.

"For many years, in an effort to meet customer needs at the point of care, companies have been unsuccessfully focusing their efforts on pushing the limits in automating PCR," said Treu in a statement. "Xagenic has taken a novel technological approach to solving the challenge of rapid, simple molecular diagnostics. The easy-to-use, affordable desktop system and future menu of tests have the ability to transform the way critical patient diagnoses are made and acted upon."

The most recent funding round followed the closing of a C$10 million Series A round in early 2012.

Xagenic was spun out of the University of Toronto in 2010.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.